Epstein Secrets

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. www.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. www.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. www.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. www.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. voNw.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archivesiedgar/data/1611746/00012139002

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 1O2021 share volumes? I'll type slower

xchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. vo.vw sec gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archivesiedgaridata/1611746/00012139002

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

Exchange Act Section 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. www.sec.gov Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002

y apologies. I think I typed too fast for many on this email. Let me state plainly what I allege: For that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you t

that, I turn directly to UBS Sell Side Analyst Alex Kramm who had quite the exchange with Cifu on the 10 2021 earnings call earlier this month. Mr Kramm: based on my analysis below, tell everyone WHY you think Cifu chose to be "Less transparent" with regards to 10 2021 share volumes? I'll type slowe

tion 17(a) and Rule 17a-8 thereunder and Eide was a cause of Aegis' violations. yo.vw sec gov EFTA00010847 Stetson: Honig side kick. Therapix now SciSparc. Still Israel Beginning on pg 10 of the SciSparc SEC approved and reviewed registration https://www.sec.gov/Archives/edgar/data/1611746/00012139002